Technology area: Biotechnology & Pharmaceuticals
42 pending office actions • 10 clients • 38 examiners • 23 art units • 0 of 42 (0%) have an AI response strategy ready • 53 patents granted in the last 365 days
Lathrop GPM LLP | Sanofi-Aventis operates in Biotechnology & Pharmaceuticals and has 6,812 career applications. It records 44 pending office actions and a resolved allowance rate of 83.14%. The rate shows allowance as the recorded result for most resolved matters, while leaving a portion resolved without allowance.
Allowed matters average 3.49 office actions per allowance. This measure describes prosecution activity associated with allowance, whereas the allowance rate describes the resolution outcome. The pending docket identifies current work, and the application history supplies broader context for practitioners assessing workload, outcome patterns, and the office-action effort reflected in the profile.
Based on the USPTO statutory response window for each pending office action. 10 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 10 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 4 (10%) |
| §103 only | 7 (17%) |
| §112 only | 8 (19%) |
| Double-patenting only | 2 (5%) |
| Double-patenting + other | 9 (21%) |
| Multi-statute (no §101) | 10 (24%) |
| No statute on record | 2 (5%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| POPA, ILEANA | 2 | 21.7% | +15.7% |
| LI, RUIXIANG | 2 | 59.5% | +18.7% |
| BRETZ, COREY LANE | 2 | 0.0% | +0.0% |
| HUYNH, PHUONG N | 2 | 65.8% | +53.6% |
| MARCSISIN, ELLEN JEAN | 1 | 34.6% | +49.4% |
| CHORBAJI, MONZER R | 1 | 76.3% | +21.5% |
| AUDET, MAURY A | 1 | 50.1% | +23.9% |
| RONEY, CELESTE A | 1 | 63.0% | +17.4% |
| PIPIC, ALMA | 1 | 54.8% | +54.3% |
| HINES, JANA A | 1 | 53.2% | +39.4% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18130980 | COMPOSITIONS AND METHODS FOR TREATING POLYMYALGIA RHEUMATICA BY ADMINISTERING AN IL-6R ANTAGONIST | HOWARD, ZACHARY C | 127d overdue |
| 17915215 | Targeted Inhibition Using Engineered Oligonucleotides | MCKILLOP, JOHN CHARLES | 8d overdue |
| 18555439 | "Good" buffer-based cationic lipids | SHOMER, ISAAC | 9d |
| 17450629 | PROCESS OF PREPARING MRNA-LOADED LIPID NANOPARTICLES | POPA, ILEANA | 9d |
| 18296283 | TARGETED GENE THERAPY FOR DM-1 MYOTONIC DYSTROPHY | BRETZ, COREY LANE | 56d |
| 18903305 | ON-COLUMN VIRAL INACTIVATION METHODS | CHORBAJI, MONZER R | — |
| 18890983 | STEREOCHEMICALLY ENRICHED COMPOSITIONS FOR DELIVERY OF NUCLEIC ACIDS | POPA, ILEANA | — |
| 18782767 | COMPOSITIONS, METHODS AND USES OF MESSENGER RNA | RONEY, CELESTE A | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17450629 | PROCESS OF PREPARING MRNA-LOADED LIPID NANOPARTICLES | POPA, ILEANA | 9d |
| 19312682 | ANTIBODY AND USE THEREOF | MARCSISIN, ELLEN JEAN | — |
| 18903305 | ON-COLUMN VIRAL INACTIVATION METHODS | CHORBAJI, MONZER R | — |
| 18890983 | STEREOCHEMICALLY ENRICHED COMPOSITIONS FOR DELIVERY OF NUCLEIC ACIDS | POPA, ILEANA | — |
| 18888602 | STABILIZED PHARMACEUTICAL FORMULATIONS OF INSULIN ANALOGUES AND/OR INSULIN DERIVATIVES | AUDET, MAURY A | — |
| 18782767 | COMPOSITIONS, METHODS AND USES OF MESSENGER RNA | RONEY, CELESTE A | — |
| 18729020 | LIPIDIC COMPOUNDS, AND USES THEREOF | PIPIC, ALMA | — |
| 18746742 | MENINGOCOCCAL B RECOMBINANT VACCINE | HINES, JANA A | — |
| Client (Assignee) | Pending OAs |
|---|---|
| TRANSLATE BIO, INC. | 11 |
| Sanofi | 8 |
| REGENERON PHARMACEUTICALS, INC. | 7 |
| GENZYME CORPORATION | 5 |
| Bioverativ Therapeutics | 4 |
| KYMAB LIMITED | 2 |
| miRecule | 2 |
| Earendil Labs Inc. | 1 |
| Kymab | 1 |
| Ablynx | 1 |
| Art Unit | Apps |
|---|---|
| 1641 | 5 |
| 1674 | 4 |
| 1637 | 3 |
| 1633 | 2 |
| 1612 | 2 |
| 1645 | 2 |
| 1675 | 2 |
| 1635 | 2 |
| 1636 | 2 |
| 1638 | 2 |
| App # | Title | Client | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|---|
| 19312682 | ANTIBODY AND USE THEREOF | Earendil Labs Inc. | MARCSISIN, ELLEN JEAN | 1677 | §112Other | Non-Final OA | — | Pending | Aug 28, 2025 |
| 18903305 | ON-COLUMN VIRAL INACTIVATION METHODS | BIOVERATIV THERAPEUTICS INC. | CHORBAJI, MONZER R | 1799 | §102§103 | Non-Final OA | — | Pending | Oct 01, 2024 |
| 18890983 | STEREOCHEMICALLY ENRICHED COMPOSITIONS FOR DELIVERY OF NUCLEIC ACIDS | Translate Bio, Inc. | POPA, ILEANA | 1633 | §101§103§112Other | Non-Final OA | — | Pending | Sep 20, 2024 |
| 18888602 | STABILIZED PHARMACEUTICAL FORMULATIONS OF INSULIN ANALOGUES AND/OR INSULIN DERIVATIVES | Sanofi | AUDET, MAURY A | 1654 | §112 | Non-Final OA | — | Pending | Sep 18, 2024 |
| 18782767 | COMPOSITIONS, METHODS AND USES OF MESSENGER RNA | Translate Bio, Inc. | RONEY, CELESTE A | 1612 | §103§112 | Non-Final OA | — | Pending | Jul 24, 2024 |
| 18729020 | LIPIDIC COMPOUNDS, AND USES THEREOF | Sanofi | PIPIC, ALMA | 1617 | §112 | Final Rejection | — | Pending | Jul 15, 2024 |
| 18746742 | MENINGOCOCCAL B RECOMBINANT VACCINE | Sanofi Pasteur Inc. | HINES, JANA A | 1645 | §103§112 | Non-Final OA | — | Pending | Jun 18, 2024 |
| 18741976 | LYME DISEASE RNA VACCINE | Sanofi Pasteur Inc. | OGUNBIYI, OLUWATOSIN A | 1645 | §101§102§103§112 | Non-Final OA | — | Pending | Jun 13, 2024 |
| 18668446 | HUMANIZED ANTI-IL-1R3 ANTIBODIES | Sanofi Biotechnology | LI, RUIXIANG | 1674 | §112 | Non-Final OA | — | Pending | May 20, 2024 |
| 18634191 | PHARMACEUTICAL FORMULATIONS CONTAINING ANTI-OX40L ANTIBODIES | Kymab Limited | JOHNSON, TIRONE DEREK | 1675 | §102§103§112DP | Non-Final OA | — | Pending | Apr 12, 2024 |
| 18626784 | TARGETED GENE THERAPY FOR DM-1 MYOTONIC DYSTROPHY | Genzyme Corporation | BRETZ, COREY LANE | 1635 | §101§102§103§112DP | Non-Final OA | — | Pending | Apr 04, 2024 |
| 18617239 | NUCLEIC ACIDS ENCODING FACTOR VIII POLYPEPTIDES WITH REDUCED IMMUNOGENICITY | BIOVERATIV THERAPEUTICS INC. | YU, DELPHINUS DOU YI | 1636 | §102§103§112 | Non-Final OA | — | Pending | Mar 26, 2024 |
| 18612039 | METHODS FOR TREATING CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) BY ADMINISTERING AN IL-4R ANTAGONIST | Regeneron Pharmaceuticals, Inc. | DONOGHUE, BRITTNEY ERIN | §102§112Other | Non-Final OA | — | Pending | Mar 21, 2024 | |
| 18592425 | ANTI-PD-L1 AND IL-2 CYTOKINES | Kymab Limited | ROONEY, NORA MAUREEN | 1641 | DP | Final Rejection | 42d overdue | Pending | Feb 29, 2024 |
| 18440711 | BACULOVIRUS EXPRESSION SYSTEM | BIOVERATIV THERAPEUTICS INC. | JACKSON III, WALTER | 1638 | §103 | Non-Final OA | — | Pending | Feb 13, 2024 |
| 18580463 | SCREENING CODON-OPTIMIZED NUCLEOTIDE SEQUENCES | Translate Bio, Inc. | GROSS, CHRISTOPHER M | 1684 | §102§103§112 | Non-Final OA | — | Pending | Jan 18, 2024 |
| 18510228 | TREATMENT OF PD-L1 NEGATIVE OR LOW EXPRESSING CANCER WITH ANTI-ICOS ANTIBODIES | Kymab Limited | LI, RUIXIANG | 1674 | §112 | Non-Final OA | — | Pending | Nov 15, 2023 |
| 18493991 | GLYCOENGINEERED Fc VARIANT POLYPEPTIDES WITH ENHANCED EFFECTOR FUNCTION | Ablynx N.V. | DAHLE, CHUN WU | 1641 | §103§112DP | Non-Final OA | — | Pending | Oct 25, 2023 |
| 18555439 | "Good" buffer-based cationic lipids | Translate Bio, Inc. | SHOMER, ISAAC | 1612 | §102§112Other | Non-Final OA | 9d | Pending | Oct 13, 2023 |
| 18286029 | IMPROVED COMPOSITIONS FOR DELIVERY OF MRNA | Translate Bio, Inc. | ZARA, JANE J | 1637 | §102§103§112DP | Non-Final OA | — | Pending | Oct 06, 2023 |
| 18463047 | HYPERGLYCOSYLATED BINDING POLYPEPTIDES | Genzyme Corporation | HUYNH, PHUONG N | 1641 | Other | Final Rejection | — | Pending | Sep 07, 2023 |
| 18455756 | TARGETED INHIBITION USING ENGINEERED OLIGONUCLEOTIDES | Mirecule, Inc. | CHONG, KIMBERLY | 1636 | §102§103§112DP | Non-Final OA | — | Pending | Aug 25, 2023 |
| 18324668 | ANTI-BCMA ANTIBODIES | Sanofi | PETERS, ALEC JON | 1641 | DP | Final Rejection | 16d | Pending | May 26, 2023 |
| 18296283 | TARGETED GENE THERAPY FOR DM-1 MYOTONIC DYSTROPHY | Genzyme Corporation | BRETZ, COREY LANE | 1635 | §101§103DP | Final Rejection | 56d | Pending | Apr 05, 2023 |
| 18130980 | COMPOSITIONS AND METHODS FOR TREATING POLYMYALGIA RHEUMATICA BY ADMINISTERING AN IL-6R ANTAGONIST | Regeneron Pharmaceuticals, Inc. | HOWARD, ZACHARY C | 1674 | §102§103§112 | Non-Final OA | 127d overdue | Pending | Apr 05, 2023 |
| 18186856 | MRNA THERAPEUTIC COMPOSITIONS AND USE TO TREAT DISEASES AND DISORDERS | Translate Bio, Inc. | SINGH, ANOOP KUMAR | 1632 | §103§112 | Non-Final OA | — | Pending | Mar 20, 2023 |
| 18185465 | PSEUDOFAB-BASED MULTISPECIFIC BINDING PROTEINS | Sanofi | HUYNH, PHUONG N | 1641 | Other | Final Rejection | — | Pending | Mar 17, 2023 |
| 17969033 | METHODS FOR TREATING PRURIGO NODULARIS BY ADMINISTERING AN IL-4R ANTAGONIST | Regeneron Pharmaceuticals, Inc. | NATARAJAN, MEERA | 1643 | §103 | Non-Final OA | 4d overdue | Pending | Mar 02, 2023 |
| 18065952 | LARGE-SCALE SYNTHESIS OF MESSENGER RNA | Translate Bio, Inc. | POHNERT, STEVEN C | 1683 | §103§112DP | Final Rejection | — | Pending | Dec 14, 2022 |
| 18045995 | FGFR3 ANTIBODIES AND METHODS OF USE | Genzyme Corporation | ALLEN, MARIANNE P | 1647 | §112 | Final Rejection | 26d | Pending | Oct 12, 2022 |
| 17915215 | Targeted Inhibition Using Engineered Oligonucleotides | Mirecule, Inc. | MCKILLOP, JOHN CHARLES | 1637 | §102§112Other | Final Rejection | 8d overdue | Pending | Sep 28, 2022 |
| 17631322 | TREATMENT OF CYSTIC FIBROSIS BY DELIVERY OF NEBULIZED mRNA ENCODING CFTR | Translate Bio, Inc. | CONNORS, ALEXANDRA F | 1634 | §112Other | Non-Final OA | — | Pending | Jan 28, 2022 |
| 17576561 | BACULOVIRUS EXPRESSION SYSTEM | BIOVERATIV THERAPEUTICS INC. | LIPPOLIS, ALEXANDRA ROSE | 1637 | §103DP | Non-Final OA | 52d overdue | Pending | Jan 14, 2022 |
| 17539659 | ENCAPSULATION OF MESSENGER RNA | Translate Bio, Inc. | MOORE, JOHN DAVID | 1638 | §112Other | Non-Final OA | — | Pending | Dec 01, 2021 |
| 17615732 | MODIFIED DOSAGE OF SUBCUTANEOUS TOCILIZUMAB FOR RHEUMATOID ARTHRITIS | Regeneron Pharmaceuticals, Inc. | DENT, ALANA HARRIS | 1643 | §103 | Non-Final OA | — | Pending | Dec 01, 2021 |
| 17450629 | PROCESS OF PREPARING MRNA-LOADED LIPID NANOPARTICLES | Translate Bio, Inc. | POPA, ILEANA | 1633 | §103Other | Non-Final OA | 9d | Pending | Oct 12, 2021 |
| 17472622 | COMPOSITIONS AND METHODS FOR mRNA DELIVERY | Translate Bio, Inc. | KIM, TAEYOON | 1631 | §103 | Final Rejection | — | Pending | Sep 11, 2021 |
| 17283433 | GENERATION OF IMPROVED HUMAN PAH FOR TREATMENT OF SEVERE PKU BY LIVER-DIRECTED GENE REPLACEMENT THERAPY | Genzyme Corporation | NICOL, ALEXANDER W | 1634 | §103 | Final Rejection | — | Pending | Apr 07, 2021 |
| 17185469 | METHOD FOR PREDICTING THE OUTCOME OF A TREATMENT WITH AFLIBERCEPT OF A PATIENT SUSPECTED TO SUFFER FROM A CANCER BY MEASURING THE LEVEL OF A PLASMA BIOMARKER | Sanofi | WEN, SHARON X | 1600 | §103DP | Non-Final OA | — | Pending | Feb 25, 2021 |
| 17112198 | METHODS FOR TREATING COPD BY ADMINISTERING AN IL-33 ANTAGONIST | Regeneron Pharmaceuticals, Inc. | BENAVIDES, JENNIFER ANN | 1675 | §103 | Non-Final OA | — | Pending | Dec 04, 2020 |
| 16863800 | METHODS FOR TREATING OR PREVENTING ASTHMA BY ADMINISTERING AN IL-33 ANTAGONIST | Regeneron Pharmaceuticals, Inc. | JOHANSEN, PETER N. | 1644 | §103DP | Final Rejection | — | Pending | Apr 30, 2020 |
| 15034531 | COMPOSITIONS FOR THE TREATMENT OF RHEUMATOID ARTHRITIS AND METHODS OF USING SAME | Regeneron Pharmaceuticals, Inc. | PAK, MICHAEL D | 1674 | §103§112DP | Non-Final OA | — | Pending | May 04, 2016 |
IP Author helps law firms respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial83.1% of resolved applications prosecuted by Lathrop Gpm LLP | Sanofi-Aventis were allowed, across 6,812 applications in USPTO records.
3.49 office actions per allowed application on average.
42 pending office actions as of October 2026, for 10 clients, before 38 examiners in 23 art units.
